Continuing the use of disease-modifying therapies (DMTs) in patients with secondary-progressive MS (SPMS) who are actively relapsing is justified, new research findings suggest.
At ECTRIMS 2018, Dr Nathaniel Lizak from the Clinical Outcomes Research (CORe) Unit at the University of Melbourne, Australia, presented the details of a study set up to evaluate factors influencing the rate of disability accumulation and progression in patients with SPMS.